Analysts predict that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.14) per share during the same quarter last year, which would suggest a positive year over year growth rate of 14.3%. The firm is expected to report its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that Evoke Pharma will report full-year earnings of ($0.41) per share for the current financial year. For the next financial year, analysts forecast that the company will report earnings of ($0.22) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04).
Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Evoke Pharma in the 1st quarter valued at about $118,000. Marshall Wace LLP acquired a new position in Evoke Pharma in the 1st quarter valued at about $139,000. Finally, BlackRock Inc. raised its stake in Evoke Pharma by 5.5% in the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,392 shares during the last quarter. 7.40% of the stock is owned by hedge funds and other institutional investors.
Evoke Pharma stock opened at $0.56 on Friday. Evoke Pharma has a 52 week low of $0.53 and a 52 week high of $3.40. The stock has a 50-day simple moving average of $0.63.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Recommended Story: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.